Full Menu Full Menu
From the Society
SHM Converge
Click here for the latest news from SHM Converge
AHA scientific statement highlights cardiorenal benefit of new diabetes drugs
Publish date: October 1, 2020
To protect the heart and kidneys, sodium-glucose transporter 2 (SGLT2) inhibitors and glucagonlike peptide–1 (GLP-1) receptor agonists should be considered for people with type 2 diabetes and chronic kidney disease (CKD), the American Heart Association advised in a new scientific statement.
Taken together, the results of relevant clinical trials indicate that SGLT2 inhibitors and GLP-1 receptor agonists safely and significantly reduce the risk for cardiovascular (CV) events, death, and the slow progression of CKD to end-stage kidney disease, including the risks for dialysis, transplantation, and death, the writing group says.
The scientific statement was published online Sept. 28 in Circulation.
"There has been rapid reporting of high-quality data in the cardio-renal-metabolic space with significant heart and kidney benefits, particularly with these two newer classes of antihyperglycemic agents," Janani Rangaswami, MD, who chaired the writing group, said in an interview.
"More recent data show benefits in chronic kidney disease and heart failure even in patients without diabetes," said Dr. Rangaswami, Einstein Medical Center and Sidney Kimmel Medical College, both in Philadelphia.
"These data are practice-changing in both cardiology and nephrology, and usher in a new era of disease-modifying therapies in heart and kidney disease," Dr. Rangaswami added.
Recommendations at a glance
Provide early and ongoing assessment of risks for CVD and CKD to patients who may benefit from SGLT2 inhibitors of GLP-1 receptor agonists.
Tailor medication choices that meet the needs of individual patients. Realize that, given "consistent class-wide effects," the choice of a specific SGLT2 inhibitor or GLP-1 receptor agonist may be dictated by affordability, coverage, and formulary considerations.
Adjust all medications in tandem with these medicines and consider the burden of polypharmacy, which is common among people with type 2 diabetes. Adjust concomitant therapies and deprescribe where possible.
Identify risks for hypoglycemia and educate patients on the signs so they can seek treatment quickly.
Monitor and control high blood pressure.
Counsel patients about the risks for and symptoms of euglycemic diabetic ketoacidosis when taking SGLT2 inhibitors, as well as classic DKA, which can be fatal.
Regularly screen and counsel patients about foot care to prevent foot ulcers or blisters that can quickly become infected and lead to amputation.
The writing group identified two additional patient subgroups that may benefit from SGLT2 inhibitors and GLP-1 receptor agonists: those with heart failure with reduced ejection fraction with or without diabetes; and those with CKD who do not have diabetes. They say more data are anticipated to validate the use of SGLT2 inhibitors and GLP-1 receptor agonists in these "at-risk" patients.
Collaborative care model
The writing group proposed a collaborative care model, bridging cardiologists, nephrologists, endocrinologists, and primary care physicians, to help facilitate the "prompt and appropriate" integration of these new classes of medications in the management of patients with type 2 diabetes and CKD.
There is "an unmet need for a cardio-renal-metabolic care model that incorporates best practices in the real world to help align these therapies, especially with vulnerable high-risk patients with cardiorenal disease, and to overcome barriers toward uptake of these agents. Hopefully this statement provides some guidance to the cardiology and nephrology communities in that area," Dr. Rangaswami said in an interview.
But old habits die hard, as research continues to show the slow adoption of these newer medications in the real world.
For example, a large observational study published last year showed a "striking" discordance between evidence-based, guideline-recommended use of SGLT2 inhibitors for the treatment of type 2 diabetes and their actual uptake in clinical practice.
Paradoxically, patients with CVD, heart failure, hypertension, CKD, and those at risk for hypoglycemia were less apt to receive an SGLT2 inhibitor than other patients.
"The relatively slow uptake of these agents is multifactorial," Dr. Rangaswami said. "Cardiologists and nephrologists may suffer from some level of 'therapeutic inertia' when using new agents they are unfamiliar with and originally branded as 'antidiabetic' agents, with the perception of these agents being outside the scope of their practice."
Two other factors are also at play. "The current health care system is based on 'specialty silos,' where specialists tend to stick to the traditional scope of their specialty and are reluctant to view these agents as part of their therapeutic armamentarium. Finally, insurance coverage barriers and affordability also limit the use on a widespread basis," Dr. Rangaswami said.
A version of this article originally appeared on Medscape.com .
EMPEROR-Reduced: Empagliflozin's HFrEF benefit solidifies class effects
The Hospitalist
COVID-19 at home: What does optimal care look like?
DAPA-CKD: SGLT2 inhibitor benefit extends to chronic kidney disease without diabetes
MIS-C cardiac evaluation requires more than EF
Observational study again suggests lasting impact of COVID-19 on heart
Children and COVID: Weekly cases resume their climb
Publish date: December 14, 2021
Epilepsy linked to 1.5-fold higher COVID-19 mortality in hospital
Treatment of opioid use disorder in hospitalized patients
D-dimer thresholds rule out PE in meta-analysis
Oral step-down therapy for infective endocarditis
Anticoagulant choice in antiphospholipid syndrome–associated thrombosis
Chronically interrupted: The importance of communication with patient and family during the COVID-19 pandemic
Publish date: December 9, 2021
Apixaban a reasonable alternative to warfarin in patients with severe renal impairment
New data on rare myocarditis after COVID-19 vaccination
The top pediatric hospital medicine articles of 2020
Does morning discharge really improve hospital throughput?
Pandemic innovations that will outlast COVID
Publish date: November 11, 2021
Geographic cohorting increased direct care time and interruptions
QI reduces daily labs and promotes sleep-friendly lab timing
AMA, hospital group sue federal government over surprise billing law
New CMS rule challenges hospitals, but not vendors, to make EHRs safer
Publish date: September 14, 2021
Biden vaccine mandate rule could be ready within weeks
Visa worries intensify pandemic stress for immigrant hospitalist moms
Publish date: June 1, 2021
A case-based framework for de-escalating conflict
Is mindfulness key to helping physicians with mental health?
Care via video teleconferencing can be as effective as in-person for some conditions
Residency programs readjust during COVID
Ten changes that could keep clinicians in the workforce in a pandemic
Did prior authorization refusals lead to this patient's death?
Hospitalists helped plan COVID-19 field hospitals
What does it mean to be a trustworthy male ally?
Reflecting on 2021, looking forward to 2022
Mean leadership
Trio of awardees illustrate excellence in SHM chapters
SHM's Center for Quality Improvement to partner on NIH grant
Publish date: August 12, 2021
Never prouder to be a hospitalist
Critical care and COVID-19: Dr. Matt Aldrich
Treatment options for COVID-19: Dr. Annie Luetkemeyer
Managing the COVID-19 isolation floor at UCSF Medical Center
DAPA-HF: Dapagliflozin's HFrEF efficacy confirmed in nondiabetics
Oral beta-lactams provide noninferior postdischarge pyelonephritis treatment
Style Guide for Authors
Hospital Leader Blog
Medication Reconciliation
Transitions of Care
An Official Publication of the Society of Hospital Medicine
Copyright by Society of Hospital Medicine or related companies. All rights reserved. ISSN 1553-085X
Medical Education Library
Current and Previous Issues
Hospice & Palliative Medicine